Global Preclinical Assets Market– Drivers
Increasing number of new test launch in the toxicology by the market players is expected to drive growth of the global preclinical assets market over the forecast period.
Increasing number of launch of new toxicology test by the key market players is expected to drive growth of the global preclinical assets market over the forecast period. For instance, in October 2018, SGS SA, a multinational company announced the launch of the in-vitro testing which consists of the development of present cell/tissue culture capabilities, flow cytometry, and mass spectrometry facilities, along with the introduction of high throughput screening, automation, and multiplexing technologies. The launch of this toxicology test will help the company to further strengthen and expand its product portfolio.
Increasing number of inorganic strategies such as acquisition by market players in North America is expected to drive growth of the global preclinical assets market over the forecast period.
Inorganic strategies such as acquisition by the key market players in North America are expected to drive growth of the global preclinical assets market over the forecast period. For instance, on May 9, 2022, Labcorp, a global life sciences company, and AtlantiCare, a health care organization in southern New Jersey, U.S., announced that they had closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey, U.S. This collaboration will help the company in further expansion of laboratory services.
Preclinical Assets Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients